← Back to Search

Other

LY3857210 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion, up to approximately 6 weeks
Awards & highlights

Study Summary

This trial is testing a new drug to see if it gets into the brain, and if it's safe. Up to four visits over six weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion, up to approximately 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through study completion, up to approximately 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scan

Trial Design

1Treatment groups
Experimental Treatment
Group I: LY3857210Experimental Treatment1 Intervention
Single doses of LY3857210 administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3857210
2022
Completed Phase 2
~430

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,200,919 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,242 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are contributing to the data of this clinical endeavor?

"Affirmative. Clinicaltrials.gov verifies that this clinical study, which was first announced on March 17th 2022 is currently enrolling patients. 25 volunteers need to be enrolled from one site for successful execution of the trial."

Answered by AI

Are there any spots left in the trial for new participants?

"Affirmative. Information hosted on clinicaltrials.gov suggests that this medical research is actively seeking out participants, having first been listed on March 17th 2022 and most recently updated September 27th 2022. A total of 25 individuals must be recruited from 1 site to meet the requirements for this trial."

Answered by AI

Does this trial accept geriatric patients?

"To take part in this trial, applicants need to be between 18 and 65 years old. For those who fall outside of these age requirements, there are 50 trials for minors and 373 studies available for seniors."

Answered by AI

What potential risks have been associated with LY3857210?

"Our team at Power judged that LY3857210's safety level is a 1 since this trial has only completed Phase 1, meaning there is limited data on its efficacy and security."

Answered by AI

Is it possible for me to participate in this clinical investigation?

"Those hoping to join this experiment must be of hale and hearty constitution, between 18 years old and 65. Thus far the trial has admitted 25 participants."

Answered by AI

Who else is applying?

What state do they live in?
Connecticut
How old are they?
18 - 65
What site did they apply to?
Invicro, Institute for Neurodegenerative Disorders
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study of LY3857210 in Healthy Participants
2022. "A Study of LY3857210 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05292040.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top